Migraine and the trigeminovascular system—40 years and counting
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Migraine and the trigeminovascular system—40 years and counting. / Ashina, Messoud; Hansen, Jakob Møller; Do, Thien Phu; Melo-Carrillo, Agustin; Burstein, Rami; Moskowitz, Michael A.
I: The Lancet Neurology, Bind 18, Nr. 8, 2019, s. 795-804.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Migraine and the trigeminovascular system—40 years and counting
AU - Ashina, Messoud
AU - Hansen, Jakob Møller
AU - Do, Thien Phu
AU - Melo-Carrillo, Agustin
AU - Burstein, Rami
AU - Moskowitz, Michael A.
PY - 2019
Y1 - 2019
N2 - The underlying causes of migraine headache remained enigmatic for most of the 20th century. In 1979, The Lancet published a novel hypothesis proposing an integral role for the neuropeptide-containing trigeminal nerve. This hypothesis led to a transformation in the migraine field and understanding of key concepts surrounding migraine, including the role of neuropeptides and their release from meningeal trigeminal nerve endings in the mechanism of migraine, blockade of neuropeptide release by anti-migraine drugs, and activation and sensitisation of trigeminal afferents by meningeal inflammatory stimuli and upstream role of intense brain activity. The study of neuropeptides provided the first evidence that antisera directed against calcitonin gene-related peptide (CGRP) and substance P could neutralise their actions. Successful therapeutic strategies using humanised monoclonal antibodies directed against CGRP and its receptor followed from these findings. Nowadays, 40 years after the initial proposal, the trigeminovascular system is widely accepted as having a fundamental role in this highly complex neurological disorder and provides a road map for future migraine therapies.
AB - The underlying causes of migraine headache remained enigmatic for most of the 20th century. In 1979, The Lancet published a novel hypothesis proposing an integral role for the neuropeptide-containing trigeminal nerve. This hypothesis led to a transformation in the migraine field and understanding of key concepts surrounding migraine, including the role of neuropeptides and their release from meningeal trigeminal nerve endings in the mechanism of migraine, blockade of neuropeptide release by anti-migraine drugs, and activation and sensitisation of trigeminal afferents by meningeal inflammatory stimuli and upstream role of intense brain activity. The study of neuropeptides provided the first evidence that antisera directed against calcitonin gene-related peptide (CGRP) and substance P could neutralise their actions. Successful therapeutic strategies using humanised monoclonal antibodies directed against CGRP and its receptor followed from these findings. Nowadays, 40 years after the initial proposal, the trigeminovascular system is widely accepted as having a fundamental role in this highly complex neurological disorder and provides a road map for future migraine therapies.
U2 - 10.1016/S1474-4422(19)30185-1
DO - 10.1016/S1474-4422(19)30185-1
M3 - Review
C2 - 31160203
AN - SCOPUS:85068529333
VL - 18
SP - 795
EP - 804
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 8
ER -
ID: 240624410